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Lithium Intoxication: A Possible Interaction with Moxifloxacin
Selvi Kayipmaz, Ali Ercan Altınöz, Nadide Elmas Gülcü Ok
Department of Psychiatry, Baskent University Faculty of Medicine, Ankara, Turkey 
Lithium is a well-known treatment for patients with mood disorders. Intoxication by lithium may be lethal particularly in elderly 
due to altered pharmacokinetics, renal impairment or multiple drug use. We presented a 74-year-old female patient who had 
been stabile with lithium carbonate 600 mg/day for 5 years and developed lithium intoxication after bronchiolitis. She presented 
with altered mental status. The neurological signs resolved slowly after lithium and moxifloxacin were stopped immediately and 
fluid resuscitation administered. Considering possible drug interactions on elderly patients receiving lithium is essential.
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INTRODUCTION
Lithium has been used for more than a half-century and 
is a well-known and established treatment for patients 
with mood disorders such as bipolar disorders and re-
current unipolar depression. Therapeutic serum lithium 
concentrations are between 0.6-1 mmol/L. Serum lithium 
concentrations above 1.2 mmol/L may cause intoxication. 
Because lithium has a narrow therapeutic index, its serum 
level must be kept within critical limits, particularly in the 
elderly.1-6) Geriatric population is more at risk of develop-
ing lithium intoxication, cause of reduced volume of dis-
tribution, decreased age-related glomerular filtration rate; 
comorbid diseases, and polypharmacy. 
Medications which are frequently used in geriatric pop-
ulation, such as angiotensin-converting enzyme (ACE) 
inhibitors, diuretics, nonsteroidal anti-inflammatory drugs 
(NSAIDs) may induce lithium toxicity.7)
Lithium intoxication may manifest with, gastrointes-
tinal (vomiting, diarrhea), renal (polyuria, polydipsia, 
acute renal failure), cardiovascular (syncope, dizziness, 
bradycardia, arrhythmias) and nervous system (drowsi-
ness, fatigue, lethargy, confusion, delirium, coma, ataxia, 
dysarthria, seizures, tremors, myoclonic jerks) symptoms. 
Lithium intoxication may be lethal, and it should be moni-
tored carefully.8,9)
Moxifloxacin is a fluoroquinolone antibiotic agent.10) 
To the best of our knowledge, lithium poisoning induced 
by the combined use of moxifloxacin and lithium in psy-
chiatric patients has never been reported. In this case re-
port, we describe a possible interaction between moxi-
floxacin and lithium in an elderly patient. 
CASE
A 74-year-old woman with a 5-year history of bipolar 
affective disorder is presented. She started on lithium car-
bonate 600 mg/day, haloperidol 10 mg/day, risperidone 2 
mg/day at her first manic episode in 2010. After she had a 
depressive episode in 2011, sertraline 25 mg/day added to 
treatment and from then until January 2016 her serum lith-
ium concentration ranged from 0.60 to 0.80 mmol/L. She 
had been maintained on lithium carbonate 300 mg in the 
morning and 300 mg at night.
She presented to the emergency department with com-
plaints of severe tremor in both hands, myoclonic jerks of 
the upper extremities, exhaustion, and slurred speech on 
January 15th, 2016. On examination, her body temper-
ature was normal and her blood pressure was 110/70 
mmHg. Her symptoms began the day after she started us-
ing moxifloxacin 400 mg/day for the treatment of bron-
chiolitis; her serum lithium concentration was 0.8 mEq/L 
10 days before. She did not have vomiting, diarrhea, nys-
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tagmus, or dysarthria. On her mental state examination, 
she was slightly drowsy and disoriented. Her speech was 
slurred. Her serum lithium concentration was 1.7 mEq/L 
(normal laboratory values 0.5-1 mEq/L). Physical exami-
nation and other laboratory tests in the emergency depart-
ment revealed no renal impairment or sign of dehydration. 
Laboratory results were as follows: fasting blood glucose, 
88 mg/dl; blood urea nitrogen, 25 mg/dl; creatinine, 0.99 
mg/dl; sodium, 139 mmol/L; potassium, 3.4 mmol/L; 
calcium, 9.2 mg/dl; alanine aminotransferase, 13 U/L; as-
partate aminotransferase, 6 U/L; creatine kinase level 
(CK), 29 U/L; CK-MB fraction, 1 ng/ml; troponin-I, 
0.016 ng/ml; lithium level, 1.7 mEq/L; white blood cell, 
7.090/l; red blood cell, 4.38 M/l; hemoglobin, 12.3 
g/dl; and hematocrit, 39%. Urinalysis results were as fol-
lows: density, 1,014; pH, 7.5; protein, 20; glucose, neg-
ative; ketone, 0 mg/dl; bilirubin, 0 mg/dl; urobilinogen, 0 
mg/dl; nitrite, negative; and leukocyte, negative. 
Neither her cranial magnetic resonance imaging nor 
electrocardiography (ECG) showed any abnormalities. 
After ruling out hypoxia, hypoglycemia, hypothermia or 
hyperthermia, electrolyte disorders, central nervous sys-
tem infection, head trauma, intracranial bleeding, and 
neuroleptic malignant syndrome, she was diagnosed with 
mild-moderate toxicity of lithium. 
Lithium and moxifloxacin were stopped immediately; 
she was administered fluid resuscitation with less than 2 L 
of 0.9% saline solution for 6 hours. After 12 hours, her se-
rum lithium concentration decreased to 0.9 mEq/L, and 
her tremors and myoclonic jerks were diminished. On the 
second day, drowsiness and disorientation were still evi-
dent, but these remaining neurological signs resolved 1 
week later.
DISCUSSION
Lithium toxicity is a life-threatening situation and par-
ticularly prevalent in elderly patients due to altered phar-
macokinetics, renal impairment, and multiple drug use. In 
elderly patients, the incidence of lithium toxicity is 1.5% 
per year.11,12) Our patient was 74 years of age and using 
multiple drugs including haloperidol, risperidone and ser-
traline; however, she was not taking diuretics, ACE in-
hibitors, or NSAIDs. Both antipsychotics and antidepres-
sants are also known to increase the risk of lithium in-
toxication when used concomitantly. It has been reported 
that combination of lithium with haloperidol, risperidone 
or serotonin reuptake inhibitors (SSRI) may cause rare 
neurotoxicity, but it is not clear that the toxicity is induced 
whether by drug interaction or effect of a single drug 
alone. On the other hand, it has been reported in pharma-
cokinetic studies that these antipsychotics and SSRIs do 
not effect lithium disposition and the serum lithium levels 
could maintain in therapeutic concentrations in case of 
intoxication.13) However, the serum lithium levels in-
creased in our case. In addition, the patient has used hal-
operidol and risperidone for 5 years and sertraline for 4 
years; but she did not have any neurotoxicity symptoms 
until the second day of moxifloxacin administration. 
Because of these reasons we focused on moxifloxacin- 
lithium interaction instead of the other drugs. 
Haloperidol, risperidone, sertraline, and moxifloxacin 
were all associated with prolongation of ECG-derived 
corrected QT interval. Combination of these drugs could 
increase the risk of QTc prolongation. However in our 
case there were no ECG abnormalities.14) 
Although other factors such as dehydration, rigorous 
dieting or low salt intake, high fever, or history of anes-
thesia or major operation have been reported to cause lith-
ium toxicity in elderly patients, no symptoms or examina-
tion results indicated such conditions in our patient. 
Result of the Naranjo Adverse Drug Reaction Probabi-
lity Scale in this case, indicated a ‘probable’ (score, 6) in-
teraction between lithium and moxifloxacin.15) 
Although serum lithium levels are useful indicators for 
toxicity, the severity of toxicity does not always correlate 
with the serum lithium concentrations. This is true espe-
cially in the elderly, in whom the symptoms frequently 
suggest a higher level of serum lithium than that actually 
present. In our patient, who had a 1.7 mEq/L serum lith-
ium concentration, we may anticipate a mild toxicity, but 
her symptoms were indicative of moderate toxicity.
Despite many reports of lithium toxicity when the anti-
biotics are prescribed concurrently with lithium therapy, 
cases in conjunction with fluoroquinolone agents are rare. 
Levofloxacin, a fluoroquinolone agent, has been re-
ported to increase the serum lithium levels. When co-ad-
ministered with lithium, levofloxacin has been reported to 
cause both renal impairment and toxicity. In addition, lev-
ofloxacin is shown to increase the serum lithium concen-
trations in rabbits without causing renal impairment.16,17)
To the best of our knowledge, there are no case reports 
of an interaction between lithium and moxifloxacin in the 
literature. Moxifloxacin is known to be a safe and 
well-tolerated fluoroquinolone antibiotic agent with a 
high patient adherence profile and is widely used in the 
elderly for the treatment of respiratory infections.9) The in-
teraction between levofloxacin and lithium interaction 
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may be explained on the basis of excretion, because they 
are both excreted renally. It is suggested that levofloxacin 
decreases the excretion of lithium by decreasing its glo-
merular filtration or tubular secretion. Although the exact 
mechanism of the interaction between lithium and moxi-
floxacin is unclear, moxifloxacin could slow down the ex-
cretion of lithium by decreasing its glomerular filtration or 
tubular secretion, similar to levofloxacin.16,17)
Further studies on potential interaction between moxi-
floxacin and lithium are needed. Physicians who pre-
scribed lithium should be careful for the possible drug 
interactions. 
Also, considering these interactions on elderly patients 
receiving lithium is essential.
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